A recent study where empagliflozin was added to RAS inhibitors for 12 weeks in people with CKD with or without diabetes and albuminuria demonstrated a significant increase in angiotensin 1–7, angiotensin I levels and upregulation of plasma renin activity in people with the diabetes (27). The gene discussed is AGT; the disease is chronic kidney disease.